Stelic Institute & Co..

tin4.jpg


July 12, 2017.

  • Stelic announced that Phase 2a study has been accepted as “Oral presentation” at 25th UEG (United European Gastroenterology) Week 2017 in Barcelona, Spain in Oct 2017, entitled “Submucosal injection of the RNA oligonucleotide STNM01 in active ulcerative colitis induces mucosal healing and reverses tissue remodeling”, which is to be presented by Professor Atreya at Erlangen University Hospital in Germany.

May 25, 2017.

  • Stelic announced that Dr. Nishimura at Tokyo Metropolitan Geriatric Hospital presented final results at Digestive Disease Week (DDW) Chicago, US, entitled “Evaluation of CHST15 Expression for Assessing the Tumor Progression and Overall Survival of EUS-Guided Intratumoral CHST15 dsRNA Injection in Patient With Unresectable Pancreatic Cancer “.
  • Link: http://www.giejournal.org/article/S0016-5107(17)30956-2/fulltext

May 15, 2017

  • STNM01 is featured as a new therapeutic target for IBD in the current issue of Nature Reviews Gastroenterology and Hepatology (volume 14, No. 5 May 2017).
  • This comprehensive review categorizes current and emerging therapies for IBD based on the mechanisms of action including modulation of barrier function, gut microbiota, matrix remodeling, macrophage and lymphocyte activation, homing and retention, as well as angiogenesis. The positioning of STNM01 in view of mechanism is defined as a new therapeutic approach targeting matrix remodeling based on the nonclinical and Phase 1 clinical studies.
  • Link: http://www.nature.com/nrgastro/journal/v14/n5/full/nrgastro.2016.208.html

May 15, 2017

  • Stelic announced the lecture presentation of positive results from Phase 2a study in patients with refractory ulcerative colitis at DDW held May 6-9, 2017 in Chicago, IL.
  • Presentation information is as follows:
  • Conference: Digestive Disease Week (DDW) 2017
  • Presentation Title: Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided ulcerative colitis patients with moderate-to-severe disease
  • Presentator: Prof. Raja Atreya, MD, PhD, Department of Medicine 1, University of Erlangen-Nürnberg
  • Session Title: IBD: Controlled Clinical Trials
  • Session Date & Time: May 9, 2017 from 10:00 AM to 11:30 AM
  • Link: http://www.gastrojournal.org/article/S0016-5085(17)30933-2/fulltext

March 28, 2017

  • Stelic announced a new peer-reviewed publication entitled “New endoscopic approach of anti-fibrotic therapy for inflammatory bowel disease” as a review article in Annals of Translational Medicine.
  • The review documents the translational practice of STNM01 from target selection to first-in-human, and depicts anti-fibrotic MOA of STNM01 based on P1 results.
  • Link: http://atm.amegroups.com/article/view/14106

March 9, 2017

  • Stelic announced a new peer-reviewed publication demonstrating the anti-fibrotic action of CHST15 siRNA in pig esophageal stricture, entitled “Prevention of esophageal stricture after endoscopic submucosal dissection using RNA-based silencing of carbohydrate sulfotransferase 15 in a porcine model” as an innovations and brief communication in Endoscopy.
  • The paper shows that endoscopic submucosal injection of CHST15 siRNA protected mice from esophageal stricture post endoscopic submucosal dissection (ESD). Although esophageal cancer could be cured by ESD technique, ESD-mediated complication such as esophageal stricture is a major problem. The new study provides a novel way to prevent the complication.
  • Link: https://www.ncbi.nlm.nih.gov/pubmed/28264215

February 20, 2017

  • Stelic announced that Phase 2a study has been accepted as “Lecture presentation” at Digestive Disease Week (DDW) in Chicago, US, in May 2017,
  • entitled “Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided Ulcerative Colitis patients with moderate-to-severe disease”,
  • which is to be presented by Professor Atreya at Erlangen University Hospital in Germany.

February 17, 2017

  • Stelic announced that Professor Atreya at Erlangen University Hospital in Germany presented Phase 2a results at ECCO and he was awarded a prize as the best oral presentation.

February 6, 2017

  • Stelic announced a new peer-reviewed publication demonstrating the anti-fibrotic action of CHST15 siRNA in murine pulmonary fibrosis, entitled “Silencing of carbohydrate sulfotransferase 15 hinders pulmonary fibrosis development.” in Molecular Therapy Nucleic Acids.
  • The paper shows that intranasal administration of CHST15 siRNA protected mice from pulmonary fibrosis-mediated lethality by blocking the activity of lung fibroblasts.
  • Link:http://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-25 31(16)30376-6

January 6, 2017

  • Stelic announced that Phase 2a study has been accepted as a Digital oral presentation at Congress of ECCO - Inflammatory Bowel Diseases 2017 in Barcelona, Spain, Entitled “Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided Ulcerative Colitis patients with moderate-to-severe disease”, which is to be presented by Professor Atreya at Erlangen University Hospital in Germany.

ページの先頭へ